Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 24, 2023 08:00 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026

STOUGHTON, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
August 07, 2023 07:30 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Announces $50 Million Accelerated Share Repurchase Program

STOUGHTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
August 03, 2023 16:01 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Reports Record 1H’23 Net Revenue of $280.3 Million, Up 35% Year-over-Year

– Q2’23 Net Revenue of $135.5 Million, Up 10% Year-over-Year – – Q2’23 GAAP Net Income of $13.0 Million – – Q2’23 Adjusted EBITDA of $85.8 Million, Up 21% Year-over-Year – – Board of Directors has...
July 20, 2023 08:00 ET | Source: Collegium Pharmaceutical, Inc.

Collegium to Report Second Quarter 2023 Financial Results on August 3, 2023

STOUGHTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
June 01, 2023 08:00 ET | Source: Collegium Pharmaceutical, Inc.

Collegium to Participate in Jefferies Healthcare Conference

STOUGHTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
May 04, 2023 16:01 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Reports First Quarter 2023 Financial Results

– Generated Record Net Revenue of $144.8 Million – – Delivered Record Belbuca® and Xtampza® ER Net Revenue – – Ended Q1’23 with Cash Balance of $269.5 Million – – Reaffirmed Full Year 2023 Guidance...
April 20, 2023 08:00 ET | Source: Collegium Pharmaceutical, Inc.

Collegium to Report First Quarter 2023 Financial Results on May 4, 2023

STOUGHTON, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
April 11, 2023 08:00 ET | Source: Collegium Pharmaceutical, Inc.

Collegium to Participate in 22nd Annual Needham Virtual Healthcare Conference

STOUGHTON, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
February 23, 2023 16:01 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results

– Generated Record Quarterly and Full-Year Net Revenue of $129.6 and $463.9 Million – – Ended 2022 with Cash Balance of $173.7 Million – – Reaffirmed 2023 Financial Guidance – – Conference...
February 22, 2023 08:00 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Publishes Inaugural 2022 Environmental, Social and Governance Report

STOUGHTON, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced the release of its...